You are here

  • Home
  • Archive
  • Volume 87, Issue 2
  • Neuropsychological impairment in natalizumab-associated progressive multifocal leukoencephalopathy: implications for early diagnosis

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Neuropsychological impairment in natalizumab-associated progressive multifocal leukoencephalopathy: implications for early diagnosis

https://doi.org/10.1136/jnnp-2014-310287

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors RH designed the study, collected and analysed the data, and drafted the manuscript. PK, SF, RS, MK, CP and RG designed the study, collected and analysed the data, and revised the manuscript. AC designed the study, collected and analysed the data, and drafted and revised the manuscript.

    • Competing interests RH received research and travel grants from BiogenIdec and travel grants from Novartis.SF received travel grants from BiogenIdec. RG declares speaker's and board honoraria from BiogenIdec, Baxter, BayerSchering, Chugai Pharmaceuticals, MerckSerono, Novartis, Roche, Sanofi-Aventis, Talecris and TEVA. He also received scientific grant support from BiogenIdec, BayerSchering, Genzyme, MerckSerono and TEVA. AC received personal compensation as a speaker or consultant for Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, UCB and Teva Neuroscience. AC received research support from the German Ministry for Education and Research (BMBF, German Competence Network Multiple Sclerosis (KKNMS; 01GI0914)), Biogen Idec, Genzyme and Novartis.

    • Ethics approval The ethics committee of Ruhr University Bochum (No. 4566-13).

    • Provenance and peer review Not commissioned; internally peer reviewed.